Ruti Aga and the Prescription From a Clinic That Never Existed: The Real Arithmetic of a Six-Year Ban

The prescription said: injection in the knee, methylprednisolone, for swelling and pain. The clinic whose name appeared on it did not exist. The person who signed it held no medical registration, and was a member of the athlete's family. Asked where the paper had come from, the answer was an old prescription pad from a former workplace. Three claims, each of which collapsed on its own ground.

In a distance runner's file, the heaviest document is usually a scan report or a load sheet. In the case of the Ethiopian marathoner Ruti Aga, the heaviest document turned out to be a prescription — and that prescription is what took her out for six years.

According to the Athletics Integrity Unit statement, Aga, 32, has been banned for six years. The sanction runs from 10 September, the same date her provisional suspension began. Two separate violations are listed: the presence of a prohibited substance in a sample taken after a half marathon in China in March — two years; and tampering — four years. The addition is plain: six years.

The first thing to settle is that this is not a performance case. Aga won that March half marathon; that much is recorded. The time, the splits, the strength of the field are not in the available material. Any comment on how she ran would be guesswork, and I do not enter guesswork in the record. What is recorded is a 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors — the file of a genuinely elite marathon career, now crossed by a six-year line.

I am writing from London, and the ground truth of this case is far from me. I do not watch the daily medical habits of Ethiopian training camps. So I will write what the documents contain, and where the documents are silent I will write the silence.

Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List, and it is prohibited in-competition only, when injected, taken orally or administered rectally. Class S1 covers the anabolic agents associated with muscle-building and recovery; an S9 glucocorticoid is an anti-inflammatory tool with no established endurance benefit. That technical distinction is the foundation of the entire case. The question was never "did she take a steroid" but "by which route, and how close to the race."

A road race's testing window opens at 23:59 the day before the race. A therapeutic knee injection given even days earlier will be caught in the sample, whatever the intent behind it. That is why the knee-injection story is not inherently implausible — intra-articular glucocorticoid treatment is routine practice among high-volume marathoners. What is implausible is the step that went towards manufacturing the paperwork instead of proving it.

An athlete holding genuine medical records would have argued route and timing — and could have won that argument. The rules also leave a therapeutic use exemption pathway open where medical need is demonstrated. Here there was no genuine record, no TUE, and no evidence of any washout calculation. All three routes appear closed, and they appear closed for the same reason.

The AIU statement documents three separate verification failures. The clinic named on the prescription did not exist. The signatory was not a registered physician. And the clinic disowned, outright, the explanation about an old prescription pad. Three independent checks, all pointing one way. Nothing was left that could be saved.

Then the arithmetic. Two years for presence, four for tampering — a six-year total consistent with the Code's standard structure, which tells us the panel did not treat the presence violation as intentional but treated the tampering as fully culpable. A two-year figure typically appears where the substance is specified and intent is unproven; the no-fault or no-significant-fault reduction available on paper was not granted. And the 10 September start is not a relief: provisional suspension time counts against the ban, so nothing is actually deducted.

One thing the statement does not say, and which I will not fill in by inference: the scope of disqualification. Standard AIU practice voids the result and prize money from the competition where the sample was collected — including, here, the March half marathon title. But the 2026 Tokyo win and the three Major second places predate that date, and absent a finding of earlier use they do not fall automatically. That is the coldest fact in the file. The record survives; the career does not.

A six-year ban at 32 means a return at roughly 38 — and in the depth of Ethiopian women's marathon running, no selector has a reason to pick a 38-year-old returning from a doping ban. Six years on paper; functionally, the end. Return-to-run is a series of small permissions — the physio's, the coach's, the organiser's, the sponsor's. When the first permission is six years long, the rest of the chain is moot.

The root cause is the knee, and that is where my concern sits. Chronic knee pathology is a known load-bearing failure mode in marathoners. The pressure to mask pain comes from the appearance-fee economy, and glucocorticoids are the cheapest, most available tool for it. When the medical structure around an athlete is informal — no credentialed team physician, no TUE culture — forging a document stops being a private moral lapse and becomes the downstream product of an untreated governance gap. I learned during the 2026 audit of Chelsea's medical for Ross Barkley how clubs discount risk, and I resolved then to be careful with "failed medical" language. The same care is owed here: this is a story about an absent medical system, not only about one athlete, and I will take the accusation exactly as far as the paperwork carries it.

At Bhubaneswar in 2026 the javelin landed gold and I was watching the elbow. The mainstream gaze goes to the result; the story sits in the joint. Here the joint is a knee, the result is a prescription, and the mainstream gaze stuck on the word "steroid."

That is where my sharpest dissent sits. Six years for a substance with no proven endurance benefit looks disproportionate at first reading, and two narratives are already queued: that the AIU was rigorous, and that this rigour falls unevenly on African road runners. I do not have a verdict between them and I am not writing to deliver one. What is visible is that the sentence came from the paper, not the substance. Had the prescription been real, this article would not exist — perhaps a two-year discussion, perhaps nothing. And the coverage that labelled the substance a steroid did its own damage, turning a timing-and-route case into something resembling a conspiracy. The paper says a treatment happened; the clinic says it does not exist. I keep both statements, and the verdict between them belongs to the panel, not to me.

Looking forward, the legacy of this case will not be that one runner left the sport. It will be that the enforcement frontier has shifted from detection to document verification. China's label-race circuit, where large appearance fees and deep East African elite fields meet, is now the AIU's highest-yield ground — the fee economy and the testing economy colliding in the same race. In the training clusters where these informal medical networks operate, more cases of this shape are unlikely to be absent. The question is not when the next ban lands. It is whether the next 24-year-old who needs a knee injection will have a family prescription pad or a registered doctor's name — and who is responsible for that difference.